| DC72671 |
AMP-Deoxynojirimycin |
AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor. |
|
| DC72672 |
7-Hydroxymethotrexate-d3 |
7-Hydroxymethotrexate-d3 is the deuterium labeled 7-Hydroxymethotrexate. 7-Hydroxymethotrexate is a major metabolite of Methotrexate. Methotrexate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. |
|
| DC72673 |
Acetyl coenzyme A trilithium |
Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis. |
|
| DC72674 |
Saccharopine hydrochloride |
Saccharopine (L-Saccharopine) hydrochloride, a lysine degradation intermediate, is a mitochondrial toxin. Lysine and α-ketoglutarate are converted into Saccharopine hydrochloride by the lysine-ketoglutarate reductase. Saccharopine hydrochloride is then oxidized to α-aminoapidate semialdehyde and glutamate by the saccharopine dehydrogenase. Saccharopine hydrochloride impairs development by disrupting mitochondrial homeostasis. |
|
| DC72675 |
TRH Precursor Peptide |
TRH Precursor Peptide is a precursor peptide of thyrotropin-releasing hormone (TRH). TRH Precursor Peptide formation of TRH in rat brain and pituitary is zinc-dependent. |
|
| DC72676 |
Mannose 1-phosphate |
Mannose 1-phosphate is an endogenous metabolite. Mannose 1-phosphate can be used to synthesize GDP-Man by the enzyme GDP-mannose pyrophosphorylase. |
|
| DC72677 |
Galactonic acid |
Galactonic acid is a sugar acid that is a metabolic breakdown product of galactose. Galactose dehydrogenase is responsible for converting galactose to galactonolactone, which then spontaneously or enzymatically converts to galactonic acid. |
|
| DC72678 |
UDP-Galactose |
UDP-Galactose is a monosaccharide involved in nucleotide sugar metabolism. UDP-Galactose and its derivatives act as a natural agonist for Gi protein-conjugated P2Y14 receptors in the immune system (IC50=0.67 μM, hP2Y14). |
|
| DC72679 |
Metanephrine |
Metanephrine is the O-methylated metabolite of epinephrine that can be used for the research of diagnosis of pheochromocytoma. |
|
| DC72680 |
PPACK II diTFA |
PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor. |
|
| DC72681 |
SPC4061 |
SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases. |
|
| DC72785 |
TP0597850
Featured
|
TP0597850 is a selective inhibitor of MMP2 (IC50=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t1/2=265 min). |
|
| DC72786 |
cis-ACCP |
cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC50 values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases. |
|
| DC72787 |
Cimoxatone |
Cimoxatone (MD 780515) is a reversible, selectively and orally active type A monoamine oxidase (MAO-A) inhibitor. Cimoxatone enhances the anorectic action of Serotonin. |
|
| DC72789 |
JUN-1111 |
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1. |
|
| DC72790 |
HKB99 |
HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 inhibits the formation of invasive pseudopodia and increases the level of PAI-2 in vitro. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC). |
|
| DC72803 |
Neuraminic acid |
Neuraminic acid is an acidic amino sugar with a backbone formed by nine carbon atoms. Neuraminic acid may also be visualized as the product of an aldol-condensation of pyruvic acid and D-mannosamine (2-amino-2-deoxy-mannose). Neuraminic acid is a functional group of some biologically active mucoproteins. |
|
| DC72818 |
INCB3619 |
INCB3619 is a selective and orally active ADAM inhibitor with IC50 of 22 nM and 14 nM for ADAM10 and ADAM17, respectively. INCB3619 has anti-tumor activity. |
|
| DC72819 |
18-Hydroxycortisol |
18-Hydroxycortisol is an endogenous steroid that secreted by the adrenal cortex. 18-Hydroxycortisol is a cortisol derivative and a steroidogenic intermediate. 18-Hydroxycortisol can be used for primary aldosteronism (PA) research. |
|
| DC72840 |
Sitagliptin fenilalanil hydrochloride |
Sitagliptin fenilalanil is a dipeptidyl aminopeptidase 4 (DPP-4) inhibitor. |
|
| DC72846 |
S-Allylmercapturic acid |
S-Allylmercapturic acid is a biomarker of food intake (BFIs) for garlic consumption. |
|
| DC72854 |
Vidofludimus hemicalcium |
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR. |
|
| DC72872 |
BDM88951 |
BDM88951 (BDM 88951) is a highly potent, selective inhibitor of endoplasmic reticulum aminopeptidase 2 (ERAP2) with IC50 of 19 nM.
BDM88951 displays selectivity index (>150) towards closely related ERAP1 and IRAP enzymes, as well as MMPs, TACE and LAP3.
BDM88951 is a potent inhibitor of ERAP2-mediated hydrolysis of two nonapeptides precursors of SIINFEKL, an ovalbumine-derived antigen, in a
dose dependent manner.
BDM88951 engage ERAP2 in cells and inhibits antigen presentation in a cellular context, also displays favorable in vitro ADME properties and in vivo exposure. |
|
| DC72892 |
MEHP
Featured
|
MEHP (Phthalic acid mono-2-ethylexyl ester) is a competitive inhibitor of CYP2C9 with IC50 of 6.37 μM. |
|
| DC72894 |
L 691816 |
L 691816 is a potent, selective and orally active inhibitors of 5-lipoxygenase. L 691816 can be used for the research of allergies and asthma. |
|
| DC72899 |
Cytidine diphosphate |
Cytidine diphosphate is a nucleoside diphosphate that acts as a carrier for phosphorylcholine, diacylglycerol, and other molecules during phospholipid synthesis. |
|
| DC72911 |
CHBO4
Featured
|
CHBO4 is a potent, reversible, competitive, and selective hMAO-B inhibitor with an IC50 value of 0.031 μM in CHBO subseries and an Ki value of 0.010 ± 0.005 μM. CHBO4 reduce cell damage by scavenging intracellular reactive oxygen species (ROS). CHBO4 can be used for Parkinson's Disease (PD) research. |
|
| DC72914 |
UE2343 |
UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2. |
|
| DC73703 |
VP15 hydrochloride |
VP15 hydrochloride (VP-15 HCl) is a BBB-penetrant, orally active, multitarget directed ligand against acetylcholine and monoamine oxidase enzymes with IC50 of 0.04 and 0.37 uM for AChE and MAO-B, respectively, >600-fold selectivity over BuChE. |
|
| DC73704 |
AD-5591
Featured
|
AD-5591 (AD5591) is a potent, selective, new generation small molecule ALDH2 activator, has the improved biological activities and pharmacological properties compared to Alda-1.
AD-5591 (100 μM) significantly increases the enzymatic activity of recombinant WT and mutant human ALDH2 proteins.
AD-5591 is the active form of AD-9308. |
|
